Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10111
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCher, Lawrence M-
dc.contributor.authorMurone, Carmel-
dc.contributor.authorLawrentschuk, Nathan-
dc.contributor.authorRamdave, Shanker-
dc.contributor.authorPapenfuss, Anthony-
dc.contributor.authorHannah, Anthony-
dc.contributor.authorO'Keefe, Graeme J-
dc.contributor.authorSachinidis, John I-
dc.contributor.authorBerlangieri, Salvatore U-
dc.contributor.authorFabinyi, Gavin C-
dc.contributor.authorScott, Andrew M-
dc.date.accessioned2015-05-15T23:27:35Z
dc.date.available2015-05-15T23:27:35Z
dc.date.issued2006-03-01-
dc.identifier.citationJournal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine; 47(3): 410-8en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/10111en
dc.description.abstractPET offers a noninvasive means to assess neoplasms, in view of its sensitivity and accuracy in staging tumors and potentially in monitoring treatment response. The aim of this study was to evaluate newly diagnosed primary brain tumors for the presence of hypoxia, as indicated by the uptake of 18F-fluoromisonidazole (18F-FMISO) and to examine the relationship of hypoxia to the uptake of 18F-FDG and molecular markers of hypoxia.Seventeen patients with suspected primary glioma were enrolled prospectively in this study. Sixteen patients had histology, with 2 having metastatic disease. All patients had PET studies with 18F-FMISO and 18F-FDG and MRI studies. Immunohistochemistry was undertaken with tumor markers of angiogenesis and hypoxia. Patients were monitored for disease progression and statistical analysis of data was performed.Of the 14 patients with histology, 8 died with a median time of 16 mo (range, 2-30 mo) until death. Of those who died, 7 had positive and 1 had negative 18F-FMISO uptake. 18F-FMISO uptake was observed in all high-grade gliomas but not in low-grade gliomas. A significant relationship was found between 18F-FDG or 18F-FMISO uptake and expression of VEGF-R1 and Ki67 expression. Other immunohistochemical markers demonstrated a trend toward increased uptake but none was significant.18F-FMISO PET provides a noninvasive assessment of hypoxia in glioma and was prognostic for treatment outcomes in the majority of patients. 18F-FMISO PET may have a role not only in directing patients toward targeted hypoxic therapies but also in monitoring response to such therapies.en
dc.language.isoenen
dc.subject.otherAdulten
dc.subject.otherAgeden
dc.subject.otherBrain.blood supply.metabolism.radionuclide imagingen
dc.subject.otherBrain Neoplasms.complications.metabolism.radionuclide imagingen
dc.subject.otherCell Hypoxiaen
dc.subject.otherFemaleen
dc.subject.otherFluorodeoxyglucose F18.diagnostic use.pharmacokineticsen
dc.subject.otherGlioma.metabolism.radionuclide imagingen
dc.subject.otherGlucose.metabolismen
dc.subject.otherHumansen
dc.subject.otherMaleen
dc.subject.otherMetabolic Clearance Rateen
dc.subject.otherMiddle Ageden
dc.subject.otherMisonidazole.analogs & derivatives.diagnostic use.pharmacokineticsen
dc.subject.otherNeovascularization, Pathologic.complications.metabolism.radionuclide imagingen
dc.subject.otherOxygen.metabolismen
dc.subject.otherRadiopharmaceuticals.diagnostic useen
dc.subject.otherStatistics as Topicen
dc.titleCorrelation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of Nuclear Medicineen
dc.identifier.affiliationCentre for PET, Austin Hospital, Heidelberg, Victoria, Australiaen
dc.description.pages410-8en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/16513609en
dc.type.contentTexten
dc.type.austinJournal Articleen
local.name.researcherBerlangieri, Salvatore U
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptClinical Haematology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptNeurosurgery-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

42
checked on Jun 12, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.